Drug Profile
Crisantaspase - Jazz Pharmaceuticals
Alternative Names: E. chrisanthemi L-asparaginase - EUSA; Asparaginase Erwinia chrysanthemi; E chrisanthemi L asparaginase; Erwina chrisanthemi L-asparaginase; Erwinase; Erwinaze; Erwinia asparaginase; Erwinia L-asparaginase - EUSA; OP-01Latest Information Update: 16 Jan 2022
Price :
$50
*
At a glance
- Originator Health Protection Agency
- Developer EUSA Pharma; Jazz Pharmaceuticals plc; Ohara Pharmaceutical
- Class Amidohydrolases; Antineoplastics; Cytostatics
- Mechanism of Action Asparaginase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Precursor cell lymphoblastic leukaemia-lymphoma
- Registered Lymphoma
Most Recent Events
- 20 Sep 2021 Porton Biopharma requests marketing approval of a BLA for Erwinaze®, which is currently under FDA review
- 30 Sep 2020 Jazz Pharmaceuticals receives Rare Pediatric Disease designation from the US FDA for Precursor cell lymphoblastic leukaemia-lymphoma
- 04 Aug 2020 Jazz Pharmaceuticals intends to launch crisantaspase in USA, in mid 2021